Vistagen Therapeutics Faces Securities Class Actions Over Alleged Misleading Phase 3 Fasedienol Disclosures

Vistagen draws multiple securities suits after Phase 3 disclosure

Allegations of Misleading Clinical Communications on Fasedienol

Vistagen Therapeutics is facing coordinated securities class actions after law firms notify investors that the company allegedly misrepresented the prospects of its intranasal fasedienol program for social anxiety disorder. The complaints contend Vistagen repeatedly framed clinical data, including from the PALISADE‑2 study, as supportive of Phase 3 success while downplaying risks that the PALISADE‑3 trial would fail to meet its primary outcome on the Subjective Units of Distress Scale (SUDS) and meaningful secondary endpoints.

Plaintiffs allege Vistagen concealed material adverse information until a December 17, 2025 corporate disclosure that, according to the complaints, acknowledged PALISADE‑3 did not demonstrate a statistically significant benefit of fasedienol versus placebo. The filings assert those statements and omissions violate Sections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b‑5, and seek to recover investor losses tied to the company’s public communications about its clinical program.

The litigation thrust raises broader questions for Vistagen’s clinical development and industry communications practices, with plaintiffs arguing that the company's representation of interim and prior trial signals created an impression of likely Phase 3 success. Beyond potential monetary liability, the suits underscore regulatory and reputational risks tied to how biotech firms describe early‑stage efficacy signals and manage investor expectations during pivotal trials.

Law firms mobilise; lead plaintiff deadline set

Three firms — Levi & Korsinsky, The Schall Law Firm and DJS Law Group — are actively soliciting investors who bought Vistagen securities between April 1, 2024 and December 16, 2025 to consider participating in litigation or seeking lead plaintiff status. The firms emphasise that appointment as lead plaintiff is optional and note a March 16, 2026 deadline for motions seeking that role; they also describe contingency arrangements and invite potential class members to review complaints and case notices.

Class status, remedies and next steps

All complaints state the class has not yet been certified, meaning investors are not represented by counsel until certification and may remain absent class members if they take no action. The lawsuits seek damages tied to the alleged inflation of market prices through misleading statements about fasedienol’s clinical prospects, and they set in motion a pre‑trial process that will address discovery of internal communications, trial data disclosures and the adequacy of Vistagen’s public statements about its pivotal program.